Published in J Biol Chem on April 05, 1996
CD28 mediates transcriptional upregulation of the interleukin-2 (IL-2) promoter through a composite element containing the CD28RE and NF-IL-2B AP-1 sites. Mol Cell Biol (1997) 1.83
Chromatin remodeling of the interleukin-2 gene: distinct alterations in the proximal versus distal enhancer regions. Nucleic Acids Res (1998) 1.12
Nuclear factor kappa B-dependent activation of the antiapoptotic bfl-1 gene by the Epstein-Barr virus latent membrane protein 1 and activated CD40 receptor. J Virol (2004) 0.96
Immunology of DNA. III. Crithidia luciliae, a simple substrate for the determination of anti-dsDNA with the immunofluorescence technique. Ann N Y Acad Sci (1975) 5.23
Genetic influence on cytokine production and fatal meningococcal disease. Lancet (1997) 4.89
The v-rel oncogene encodes a kappa B enhancer binding protein that inhibits NF-kappa B function. Cell (1990) 4.87
Cyclosporin A specifically inhibits function of nuclear proteins involved in T cell activation. Science (1989) 4.70
Increased plasma levels of interleukin-6 in sepsis. Blood (1989) 3.92
Transmission of signals from the T lymphocyte antigen receptor to the genes responsible for cell proliferation and immune function: the missing link. Annu Rev Immunol (1990) 3.55
Functional discrimination between interleukin 6 and interleukin 1. Eur J Immunol (1988) 3.51
Autoantibodies to cyclic citrullinated peptides predict progression to rheumatoid arthritis in patients with undifferentiated arthritis: a prospective cohort study. Arthritis Rheum (2004) 3.38
The 65-kDa subunit of human NF-kappa B functions as a potent transcriptional activator and a target for v-Rel-mediated repression. Proc Natl Acad Sci U S A (1992) 3.09
Prostaglandin-E2 is a potent inhibitor of human interleukin 12 production. J Exp Med (1995) 2.98
Molecular and quantitative analysis of helper T cell-replacing factors on the induction of antigen-sensitive B and T lymphocytes. J Immunol (1979) 2.79
NF-kappa B: a family of inducible and differentially expressed enhancer-binding proteins in human T cells. Proc Natl Acad Sci U S A (1990) 2.75
Interleukin 6 is involved in interleukin 1-induced activities. Eur J Immunol (1988) 2.63
Molecular cloning and expression of hybridoma growth factor in Escherichia coli. J Immunol (1987) 2.59
Construction of cDNA coding for human von Willebrand factor using antibody probes for colony-screening and mapping of the chromosomal gene. Nucleic Acids Res (1985) 2.50
Serum levels of interleukin-6 and acute phase responses. Lancet (1987) 2.44
Impact of dosage frequency on patient compliance. Diabetes Care (1997) 2.43
Full-length von Willebrand factor (vWF) cDNA encodes a highly repetitive protein considerably larger than the mature vWF subunit. EMBO J (1986) 2.35
Experimental endotoxemia in humans: analysis of cytokine release and coagulation, fibrinolytic, and complement pathways. Blood (1990) 2.33
FcgammaRI (CD64) contributes substantially to severity of arthritis, hypersensitivity responses, and protection from bacterial infection. Immunity (2002) 2.31
Interleukin 6 (IL-6) in serum and urine of renal transplant recipients. Clin Exp Immunol (1988) 2.24
Anti-dsDNA and complement profiles as prognostic guides in systemic lupus erythematosus. Arthritis Rheum (1979) 2.23
A region of the Herpesvirus saimiri genome required for oncogenicity. Science (1985) 2.22
Rheumatoid arthritis subtypes identified by genomic profiling of peripheral blood cells: assignment of a type I interferon signature in a subpopulation of patients. Ann Rheum Dis (2007) 2.22
Interleukin 10 secretion in relation to human IL-10 locus haplotypes. Proc Natl Acad Sci U S A (1998) 2.18
Benzodiazepines and the risk of falling leading to femur fractures. Dosage more important than elimination half-life. Arch Intern Med (1995) 2.13
Regulatory properties of LFA-1 alpha and beta chains in human T-lymphocyte activation. Nature (1988) 2.09
Relevance of the tumor necrosis factor alpha (TNF alpha) -308 promoter polymorphism in TNF alpha gene regulation. J Inflamm (1997) 2.05
On the interaction of IgG subclasses with the low affinity Fc gamma RIIa (CD32) on human monocytes, neutrophils, and platelets. Analysis of a functional polymorphism to human IgG2. J Clin Invest (1992) 2.04
Decreased interleukin-10 and increased interleukin-12p40 mRNA are associated with disease activity and characterize different disease stages in multiple sclerosis. Ann Neurol (1999) 1.99
The purification and quantitation of helper T cell-replacing factors secreted by murine spleen cells activated by concanavalin A. J Immunol (1979) 1.95
Activation of interleukin-2 gene transcription via the T-cell surface molecule CD28 is mediated through an NF-kB-like response element. J Biol Chem (1991) 1.92
Construction of replication-competent Herpesvirus saimiri deletion mutants. J Virol (1984) 1.89
Interleukin-8 in sepsis: relation to shock and inflammatory mediators. Infect Immun (1992) 1.85
Pharmaco-morbidity linkage: a feasibility study comparing morbidity in two pharmacy based exposure cohorts. J Epidemiol Community Health (1992) 1.81
A growth-factor dependent B-cell hybridoma. Curr Top Microbiol Immunol (1986) 1.79
Endothelial plasminogen activator inhibitor (PAI): a new member of the Serpin gene family. EMBO J (1986) 1.78
The effect of interleukin-1, interleukin-6 and its interrelationship on the synthesis of serum amyloid A and C-reactive protein in primary cultures of adult human hepatocytes. Biochem Biophys Res Commun (1988) 1.76
An IL-13 promoter polymorphism associated with increased risk of allergic asthma. Genes Immun (1999) 1.75
Regulation of bioactive IL-12 production in lipopolysaccharide-stimulated human monocytes is determined by the expression of the p35 subunit. J Immunol (1996) 1.74
Discovery of distinctive gene expression profiles in rheumatoid synovium using cDNA microarray technology: evidence for the existence of multiple pathways of tissue destruction and repair. Genes Immun (2003) 1.70
Conditional identification of phosphate-starvation-response mutants in Arabidopsis thaliana. Planta (2000) 1.68
Immunology of DNA. IV. Quantitative aspects of the Farr assay. J Immunol Methods (1976) 1.66
Absence of jaagsiekte sheep retrovirus DNA and RNA in bronchioloalveolar and conventional human pulmonary adenocarcinoma by PCR and RT-PCR analysis. Hum Pathol (2001) 1.66
Recombinant human monoclonal antibodies to Ebola virus. J Infect Dis (1999) 1.65
Parathyroid hormone (PTH) and PTH-like protein (PLP) stimulate interleukin-6 production by osteogenic cells: a possible role of interleukin-6 in osteoclastogenesis. Biochem Biophys Res Commun (1989) 1.64
Chloroquine and hydroxychloroquine equally affect tumor necrosis factor-alpha, interleukin 6, and interferon-gamma production by peripheral blood mononuclear cells. J Rheumatol (1997) 1.63
Immunology of DNA. I. The influence of reaction conditions on the Farr assay as used for the detection of anti-ds DNA. J Immunol Methods (1976) 1.63
Sex differences in the pharmacological treatment of hypertension: a review of population-based studies. J Hypertens (1997) 1.62
Role of cytokines in sepsis. Adv Immunol (1997) 1.60
Structure-function relationship of human von Willebrand factor. Blood (1987) 1.60
Interleukin (IL)-4 production by human T cells: differential regulation of IL-4 vs. IL-2 production. Eur J Immunol (1992) 1.57
Neuropsychiatric systemic lupus erythematosus is associated with imbalance in interleukin 10 promoter haplotypes. Ann Rheum Dis (1999) 1.55
Tissue distribution of human minor histocompatibility antigens. Ubiquitous versus restricted tissue distribution indicates heterogeneity among human cytotoxic T lymphocyte-defined non-MHC antigens. J Immunol (1992) 1.55
Is there a future for TNF promoter polymorphisms? Genes Immun (2004) 1.54
Peptides which bind to E-selectin and block neutrophil adhesion. J Biol Chem (1995) 1.48
A gene for dihydrofolate reductase in a herpesvirus. Science (1988) 1.47
Non-puerperal lactation associated with antidepressant drug use. Br J Clin Pharmacol (1997) 1.46
TNF-alpha promoter polymorphisms, production and susceptibility to multiple sclerosis in different groups of patients. J Neuroimmunol (1997) 1.43
Secretion of anti-citrulline-containing peptide antibody by B lymphocytes in rheumatoid arthritis. Arthritis Rheum (2001) 1.42
Tumour necrosis factor alpha gene polymorphisms and rheumatic diseases. Br J Rheumatol (1998) 1.39
Tumor necrosis factor (TNF) inhibits interleukin (IL)-1 and/or IL-6 stimulated synthesis of C-reactive protein (CRP) and serum amyloid A (SAA) in primary cultures of human hepatocytes. Biochim Biophys Acta (1991) 1.38
Characterization of two classes of ribonucleoprotein complexes possibly involved in RNA editing from Leishmania tarentolae mitochondria. EMBO J (1994) 1.36
Tumour necrosis factor alpha gene polymorphisms in rheumatoid arthritis: association with susceptibility to, or severity of, disease? Br J Rheumatol (1997) 1.36
RFLP for a human von Willebrand factor (vWF) cDNA clone, pvWF1100. Nucleic Acids Res (1985) 1.36
Prognostic value of anti-dsDNA in SLE. Ann Rheum Dis (1982) 1.35
A subtype of multiple sclerosis defined by an activated immune defense program. Genes Immun (2006) 1.35
Signals involved in T cell activation. T cell proliferation induced through the synergistic action of anti-CD28 and anti-CD2 monoclonal antibodies. Eur J Immunol (1988) 1.34
Imaging and serum analysis of immune complex formation of radiolabelled infliximab and anti-infliximab in responders and non-responders to therapy for rheumatoid arthritis. Ann Rheum Dis (2006) 1.34
Defective TCR-mediated signaling in synovial T cells in rheumatoid arthritis. J Immunol (1997) 1.34
Production and characterization of monoclonal antibodies raised against recombinant human granzymes A and B and showing cross reactions with the natural proteins. J Immunol Methods (1993) 1.33
Covalent dimerization of vascular permeability factor/vascular endothelial growth factor is essential for its biological activity. Evidence from Cys to Ser mutations. J Biol Chem (1994) 1.33
Detection of antibodies to DNA by radioimmunoassay and immunofluorescence. Scand J Rheumatol Suppl (1975) 1.30
Expression of the thioredoxin-thioredoxin reductase system in the inflamed joints of patients with rheumatoid arthritis. Arthritis Rheum (1999) 1.29
Induction of insulin resistance by androgens and estrogens. J Clin Endocrinol Metab (1994) 1.28
Induction of T cell proliferation with anti-CD3 switch-variant monoclonal antibodies: effects of heavy chain isotype in monocyte-dependent systems. Eur J Immunol (1987) 1.27
Activation of the STAT1 pathway in rheumatoid arthritis. Ann Rheum Dis (2004) 1.26
Development of a human interleukin-6 receptor antagonist. J Biol Chem (1994) 1.25
Structure-function analysis of human IL-6. Epitope mapping of neutralizing monoclonal antibodies with amino- and carboxyl-terminal deletion mutants. J Immunol (1990) 1.25
Induction of immunoglobulin synthesis by interleukin 2 is T4+/T8- cell dependent. A role for interleukin 2 in the pokeweed mitogen-driven system. Eur J Immunol (1985) 1.24
The origin and molecular characterization of adenoid basal carcinoma of the uterine cervix. Int J Gynecol Pathol (1997) 1.24
IL-6 is an intermediate in IL-1-induced thymocyte proliferation. J Immunol (1989) 1.23
Genetic influence on cytokine production in meningococcal disease. Lancet (1997) 1.23
Interleukin-6 (IL-6) in synovial fluid and serum of patients with rheumatic diseases. Scand J Rheumatol (1988) 1.22
Cardiovascular diseases and risk factors in a population-based study in The Netherlands: agreement between questionnaire information and medical records. Neth J Med (1999) 1.22
Histone and DNA detection in swollen spermatozoa and somatic cells, by immunofluorescence. Clin Exp Immunol (1976) 1.21
Detection of anti-dsDNA as diagnostic tool. Ann Rheum Dis (1981) 1.21
Inhibition of cytokine production by methotrexate. Studies in healthy volunteers and patients with rheumatoid arthritis. Rheumatology (Oxford) (2003) 1.20
Reduced production of IL-12 and IL-12-dependent IFN-gamma release in patients with allergic asthma. J Immunol (1997) 1.20
Histamine inhibits the production of interleukin-12 through interaction with H2 receptors. J Clin Invest (1998) 1.20
TNF-308A and HLA-DR3 alleles contribute independently to susceptibility to systemic lupus erythematosus. Arthritis Rheum (2000) 1.20
Displacement of linker for activation of T cells from the plasma membrane due to redox balance alterations results in hyporesponsiveness of synovial fluid T lymphocytes in rheumatoid arthritis. J Immunol (2000) 1.19
Characterization of an interleukin-6-mediated autocrine growth loop in the human multiple myeloma cell line, U266. Blood (1991) 1.19
Carcinosarcomas (malignant mixed mullerian tumors) of the female genital tract: comparative molecular analysis of epithelial and mesenchymal components. Hum Pathol (1998) 1.18
Evidence for the role of an altered redox state in hyporesponsiveness of synovial T cells in rheumatoid arthritis. J Immunol (1997) 1.18
Activation of toll-like receptors 2 and 4 by gram-negative periodontal bacteria. Oral Microbiol Immunol (2007) 1.18